GOLDMAN SACHS GROUP INC (WSLS OFFSHORE INVESTMENTS, SLP) sold $2.3M of ATTO (indirect holdings)

GOLDMAN SACHS GROUP INC sold 105,807 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $21.28 ($20.84–$22.19, $2.25M total) across 23 trades on 2026-08-05. Filed jointly with GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., WSLS OFFSHORE INVESTMENTS, SLP, West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P. and WSLS EMP ONSHORE INVESTMENTS, L.P..

Original reporting
SEC EDGAR · GOLDMAN SACHS GROUP INC, GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., WSLS OFFSHORE INVESTMENTS, SLP, West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P., WSLS EMP ONSHORE INVESTMENTS, L.P.
Published Aug 14, 2026, 1:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 2:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATTO
Neutral
medium confidence
Mentioned
$ATTO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATTONeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale totaling about $2.25M and the resulting 0-share position for the reporting group’s indirect holdings.

02

Market read

Traders may monitor ATTO for any clustering of similar sales by other holders, but this filing alone does not provide a new fundamental catalyst.

03

What to watch

Indirect holdings and multi-entity joint filers can obscure who ultimately bears the economic exposure; absence of a stated 10b5-1 plan does not confirm information content.

Relevance 6/10Novelty 3/10Timing: filed Aug 13, covering Aug 5 sale

Background

This is an SEC Form 4 insider transaction disclosure for Attovia Therapeutics, Inc. (ATTO), reported by Goldman Sachs Group Inc and related entities as indirect holders.

Company-level read

Ticker impact

$ATTONeutralMedium confidence
Context

Goldman Sachs Group reported an indirect open-market sale of 105,807 ATTO shares at a weighted avg $21.2808, leaving 0 shares.

Expected impact

Likely limited, short-lived sentiment impact; any follow-through would depend on whether other holders also reduce exposure.

Evidence & confidence

Form 4 shows a one-time sale with no 10b5-1 plan stated and no accompanying company-specific news (no guidance, trial, or deal). The transaction size is moderate, and indirect sales often have non-informational motives.

Market effects

Minimal sector read-through because the disclosure is a single-company insider sale without operational or regulatory context.

None indicated.

None indicated.

Counterpoint

The sale could be routine rebalancing or tax-related, so it may not reflect negative expectations for ATTO.

Key entities

  • Attovia Therapeutics, Inc.

    Subject of the Form 4 disclosure; 105,807 shares sold indirectly, leaving 0 shares.

  • Goldman Sachs Group Inc

    Reporter of the indirect open-market sale via multiple co-reporting entities.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$ATTOMedAI 8/10

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

$ATTOMedAI 8/10

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.